Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine
Antineoplastic Combined Chemotherapy Protocols
In patients with metastatic pancreatic adenocarcinoma, nab-paclitaxel plus gemcitabine significantly improved overall survival, progression-free survival, and response rate, but rates of peripheral neuropathy and myelosuppression were increased. (Funded by Celgene; ClinicalTrials.gov number, NCT00844649.).